The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains
Abstract
The results of vancomycin susceptibility tests document that the drug continues to have activity against a wide variety of gram-positive pathogens. The subsequent emergence of vancomycin-resistant enterococci, the persistent failure of vancomycin therapy against strains tested as susceptible, and the more recent discoveries of vancomycin-intermediate or -resistant Staphylococcus aureus strains have compromised the use of vancomycin. Although analyses of surveillance studies fail to demonstrate "minimum inhibitory concentration creep" among populations of wild-type enterococci, streptococci, or staphylococci, enterococci with acquired resistance to vancomycin continue to evolve. The dominantly used automated commercial tests poorly recognize vancomycin-intermediate S. aureus, heteroresistant vancomycin-intermediate S. aureus, and vancomycin-resistant S. aureus isolates, which necessitates the use of expensive supplemental screening tests. Monitoring for appropriate serum levels of vancomycin and determinations of the bactericidal activity of vancomycin appear to best predict clinical outcome, thus creating additional diagnostic burdens for clinical laboratories. Improvements in current test methods with breakpoint criteria and expanded use of the vancomycin bactericidal assays to detect "tolerant" strains will be required to increase the value of vancomycin treatment or to refocus therapy toward the use of newer, alternative agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Manual of clinical microbiology
Drasar, B. (2003) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(03)90074-5 · Cited by 2,594
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
VANCOMYCIN-RESISTANT ENTEROCOCCI
Uttley, A. C., Collins, C. H., Naidoo, J., & George, R. C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91037-9 · Cited by 1,226
Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard
Wikler, M. A., & Clinical (2012) · Medical Entomology and Zoology · Cited by 895
Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus
Weigel, L. M., Clewell, D. B., Gill, S. R., Clark, N. C., McDougal, L. K., Flannagan, S. E., Kolonay, J. F., Shetty, J., Killgore, G. E., & Tenover, F. C. (2003) · Science · doi:10.1126/science.1090956 · Cited by 889
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Structure, biochemistry and mechanism of action of glycopeptide antibiotics
Reynolds, P. E. (1989) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01967563 · Cited by 699
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Emergence of Vancomycin Resistance in Coagulase-Negative Staphylococci
Schwalbe, R. S., Stapleton, J. T., & Gilligan, P. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161507 · Cited by 584
Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
(2001) · PsycEXTRA Dataset · doi:10.1037/e548302006-001 · Cited by 564
Brent, L. (1983) · PubMed · Cited by 561
Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus
Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.5-14.2003 · Cited by 492
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981
Farber, B. F., & Moellering, R. C. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.1.138 · Cited by 432
Multiple Antibiotic Resistance in a Bacterium with Suppressed Autolytic System
TOMASZ, A., ALBINO, A., & ZANATI, E. (1970) · Nature · doi:10.1038/227138a0 · Cited by 429
Wootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414
STAPHYLOCOCCUS AUREUS RESISTANT TO VANCOMYCIN???UNITED STATES, 2002
&NA; (2002) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200203000-00016 · Cited by 395
Charles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P., & Grayson, M. L. (2004) · Clinical Infectious Diseases · doi:10.1086/381093 · Cited by 384
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.4.1020-1027.1998 · Cited by 376
Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania
Tenover, F. C., Weigel, L. M., Appelbaum, P. C., McDougal, L. K., Chaitram, J., McAllister, S., Clark, N., Killgore, G., O'Hara, C. M., Jevitt, L., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.275-280.2004 · Cited by 370
Hanaki, H. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.199 · Cited by 366
Sakoulas, G., Eliopoulos, G. M., Moellering, R. C., Wennersten, C., Venkataraman, L., Novick, R. P., & Gold, H. S. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1492-1502.2002 · Cited by 364
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., McAllister, S. K., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2167-2167.1998 · Cited by 362
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344
Moise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A., & Moellering, R. C. (2004) · Clinical Infectious Diseases · doi:10.1086/421092 · Cited by 332
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
Ploy, M., Grelaud, C., Martin, C., de Lumley, L., & Denis, F. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79166-2 · Cited by 331
Liu, C., & Chambers, H. F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3040-3045.2003 · Cited by 321
Walsh, T. R., Bolmström, A., Qwärnström, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P., & Diekema, D. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2439-2444.2001 · Cited by 319
Cui, L., Murakami, H., Kuwahara-Arai, K., Hanaki, H., & Hiramatsu, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2276-2285.2000 · Cited by 318
Weinstein, R. A., & Fridkin, S. K. (2001) · Clinical Infectious Diseases · doi:10.1086/317542 · Cited by 304
Historical Yearly Usage of Vancomycin
Kirst, H. A., Thompson, D. G., & Nicas, T. I. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1303 · Cited by 276
Vancomycin-resistant Staphylococcus aureus
Howe, R. A., Bowker, K. E., Walsh, T. R., Feest, T. G., & MacGowan, A. P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78597-4 · Cited by 274
A NEW TYPE OF PENICILLIN RESISTANCE OF STAPHYLOCOCCUS AUREUS
(1977) · InPharma · doi:10.1007/bf03284982 · Cited by 253
Vancomycin-resistant Staphylococcus aureus--New York, 2004.
(2004) · PubMed · Cited by 252
The Antimicrobic Susceptibility Test: Principles and Practices.
(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-388_1 · Cited by 244
Production of l-DOPA by Aspergillus terreus
Chattopadhyay, S., & Das, A. (1990) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1990.tb03888.x · Cited by 243
Vancomycin-Resistant Staphylococcus aureus--Pennsylvania, 2002
(2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.17.2116 · Cited by 228
Bozdogan, B. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg457 · Cited by 225
Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996
(1997) · American Journal of Infection Control · doi:10.1016/s0196-6553(97)90087-0 · Cited by 224
The Importance of Bactericidal Drugs: Future Directions in Infectious Disease
Finberg, R. W., Moellering, R. C., Tally, F. P., Craig, W. A., Pankey, G. A., Dellinger, E. P., West, M. A., Joshi, M., Linden, P. K., Rolston, K. V., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/425009 · Cited by 216
The Prevalence and Mechanisms of Vancomycin Resistance in Staphylococcus Aureus
Walsh, T. R., & Howe, R. A. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160806 · Cited by 215
Antibiotic tolerance among clinical isolates of bacteria
Tuomanen, E., Durack, D. T., & Tomasz, A. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.4.521 · Cited by 212
Antibiotic Tolerance Among Clinical Isolates of Bacteria
Handwerger, S., & Tomasz, A. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.3.368 · Cited by 206
A NEW TYPE OF PENICILLIN RESISTANCE OF STAPHYLOCOCCUS AUREUS
Sabath, L. D., Laverdiere, M., Wheeler, N., Blazevic, D., & Wilkinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91941-9 · Cited by 205
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study
Ena, J. (1993) · JAMA · doi:10.1001/jama.269.5.598 · Cited by 203
Sakoulas, G., Eliopoulos, G. M., Moellering, Jr., Novick, R. P., Venkataraman, L., Wennersten, C., DeGirolami, P. C., Schwaber, M. J., & Gold, H. S. (2003) · The Journal of Infectious Diseases · doi:10.1086/368128 · Cited by 187
Akins, R. L., & Rybak, M. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.454-459.2001 · Cited by 179
Jones, R. N. (2003) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2003-37923 · Cited by 167
Self-citationMoore, M. R., Perdreau‐Remington, F., & Chambers, H. F. “. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1262-1266.2003 · Cited by 149
Vancomycin‐ResistantStaphylococcus aureusin the Absence of Vancomycin Exposure
Whitener, C., Park, S. Y., Browne, F. A., Parent, L. J., Julian, K. G., Bozdoğan, B., Appelbaum, P. C., Chaitram, J. M., Weigel, L. M., Jernigan, J. A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/382357 · Cited by 148
Vancomycin-Intermediate Staphylococcus aureus in Korea
Kim, M., Pai, C. H., Woo, J. H., Ryu, J. S., & Hiramatsu, K. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.10.3879-3881.2000 · Cited by 142
Flannagan, S. E., Chow, J. W., Donabedian, S. M., Brown, W. J., Perri, M. B., Zervos, M., Ozawa, Y., & Clewell, D. B. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3954-3959.2003 · Cited by 133
Marchese, A. E., Balistreri, G., Tonoli, E., Debbia, E. A., & Schito, G. C. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.2.866-869.2000 · Cited by 123
Isolation in Brazil of NosocomialStaphylococcus aureusWith Reduced Susceptibility to Vancomycin
Oliveira, G. A., Dell'aquila, A., Masiero, R. L., Levy, C. E., Gomes, M. S., Cui, L., Hiramatsu, K., & Mamizuka, E. M. (2001) · Infection Control and Hospital Epidemiology · doi:10.1086/501932 · Cited by 118
Presence of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Germany
Bierbaum, G., Fuchs, K., Lenz, W., Szekat, C., & Sahl, H. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050380 · Cited by 114
Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999.
Khurshid, M., Chou, T. D., Carey, R. A., Larsen, R. A., Conover, C. S., & Bornstein, S. (2000) · MMWR Morbidity and Mortality Weekly Report · Cited by 109
The Emergence of Decreased Susceptibility to Vancomycin in Staphylococcus epidermidis
Garrett, D. O., Jochimsen, E. M., Murfitt, K. C., Hill, B. C., McAllister, S. K., Nelson, P., Spera, R. V., Sall, R. K., Tenover, F. C., Johnston, J., et al. (1999) · Infection Control and Hospital Epidemiology · doi:10.1086/501605 · Cited by 106
Denis, O., Nonhoff, C., Byl, B., Knoop, C., Bobin-Dubreux, S., & Struelens, M. J. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf142 · Cited by 95
Epidemiology of the Genetic Elements Responsible for Acquired Glycopeptide Resistance in Enterococci
Woodford, N. (2001) · Microbial Drug Resistance · doi:10.1089/10766290152652774 · Cited by 90
Hubert, S. K., Mohammed, J. M., Fridkin, S. K., Gaynes, R. P., McGowan, J. E., & Tenover, F. C. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.11.3590-3593.1999 · Cited by 84
Problems in in vitro determination of antibiotic tolerance in clinical isolates
Sherris, J. C. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.5.633 · Cited by 76
Best, G. K., Best, N. H., & Koval, A. V. (1974) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.6.6.825 · Cited by 74
Currie, B. P., & Lemos-Filho, L. B. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4427-4429.2004 · Cited by 61
Special Phenotypic Methods for Detecting Antibacterial Resistance
Limbago, B. M., & Swenson, J. M. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch73 · Cited by 56
Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus
Howe, R. A., Wootton, M., Walsh, T. R., Bennett, P. M., & MacGowan, A. P. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.5.675 · Cited by 52
Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.
(2000) · PubMed · Cited by 50
Périchon, B., & Courvalin, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4281-4285.2004 · Cited by 44
LaPlante, K. L., & Rybak, M. J. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.06.014 · Cited by 43
Verdier, I., Reverdy, M. E., Étienne, J., Lina, G., Bes, M., & Vandenesch, F. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1024-1027.2004 · Cited by 40
Asseray, N., Jacqueline, C., Mabecque, V. L., Batard, É., Bugnon, D., Potel, G., & Caillon, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.857-859.2005 · Cited by 26
Barry, A. L., Jones, R. N., GAVAN, T. L., & Thornsberry, C. (1987) · Journal of Clinical Microbiology · doi:10.1128/jcm.25.9.1812-1814.1987 · Cited by 23
Self-citationA Mouse Peritonitis Model for the Study of Glycopeptide Efficacy in GISA Infections
Doménech, A., Ribes, S., Cabellos, C., Domínguez, M. Á., Montero, A., Liñares, J., Ariza, J., & Gudiol, F. (2004) · Microbial Drug Resistance · doi:10.1089/mdr.2004.10.346 · Cited by 23
The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland
Krzysztoń-Russjan, J. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf252 · Cited by 23
Rybak, M. J., Cha, R., Cheung, C. M., Meka, V. G., & Kaatz, G. W. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.09.005 · Cited by 22
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Management of multidrug-resistant organisms in health care settings, 2006
Siegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.006 · Cited by 1,283
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Metadata
- Authors
- Jones, R. N.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-01-01
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S13-S24
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2135044274
- Cited by
- 254
- References
- 82
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.